Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISE-HF: Caficrestat in Diabetic Cardiomyopathy
NCT04083339Phase 3Active, not recruiting
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of caficrestat in diabetic cardiomyopathy (DCM), sponsored by Applied Therapeutics, Inc.. Started Sep 2019; status: active, not recruiting.
02
Drugs
caficrestat
03
Conditions
diabetic cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT04083339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083339.